Cagrilintide and semaglutide

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

ObesityObesity & OverweightOverweight

Phase 1

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

CompletedNCT04940078

Novo Nordisk A/SObesity & Overweight

Start: 2021-07-07End: 2022-02-16Updated: 2025-12-12

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

CompletedNCT06267092

Novo Nordisk A/SObesity, Overweight

Start: 2024-02-15End: 2025-12-08Updated: 2026-01-08